NCT02878564View on ClinicalTrials.gov

Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Schistosomiasis MansoniHIV
Interventions
DRUG

Praziquantel

40 mg/kg, PO (orally administered tablets)

Trial Locations (1)

Unknown

UVRI-IAVI HIV Vaccine program, Entebbe

All Listed Sponsors
collaborator

UVRI-IAVI HIV Vaccine Program, Uganda

UNKNOWN

lead

University of Toronto

OTHER

NCT02878564 - Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology | Biotech Hunter | Biotech Hunter